Eurofins CDMO Alphora Inc. Announces the Completion of a New Pilot Scale Biologics Development Facility
January 17 2024 - 9:00AM
Business Wire
Eurofins (Paris:ERF):
Eurofins CDMO Alphora Inc. (Eurofins Alphora), a Contract Drug
and Manufacturing Organization based in Mississauga, Canada, is
excited to announce the successful completion of its pilot-scale
biologics development facility. Spanning 3,300 square feet, the
facility is dedicated to the development and scaling of monoclonal
antibodies (mAbs) and other mammalian-based therapeutic proteins.
The facilities’ offerings include upstream and downstream
development, process design, analytical development, GMP QC
testing, GMP Cell-Based Assays, and scale-up capacity to 200L for
pre-clinical and phase I supply.
Equipped with cutting-edge technology, the facility can
accommodate diverse batch sizes, both fedbatch and perfusion.
Leveraging a skilled team of bioprocess scientists and
state-of-the-art equipment, such as the Amber 250 and BioProfile
FLEX2 Automated Cell Culture Analyzer, Eurofins Alphora prioritizes
rapid market entry by implementing efficient, science-based
scale-up strategies. The analytical laboratory offers a wide range
of analytical testing and bio-assays for both GMP and non-GMP
applications, supporting process and drug candidate
characterization. This integrated solution enables clients to
streamline timelines and reduce development costs in manufacturing
biologic drug candidates.
Coupled with extensive experience in linker and warhead
development through its expertise in active pharmaceutical
ingredients (API) and highly potent active pharmaceutical
ingredients (HPAPI), Eurofins Alphora’s added biologics capacity
supports fully integrated conjugation services for antibody drug
conjugate (ADC) candidate development.
To learn more, please visit: www.eurofins.com/cdmo
About Eurofins CDMO Eurofins Alphora Inc. Eurofins CDMO
Alphora Inc. is a leading global Contract Development and
Manufacturing Organization that provides clients with active
pharmaceutical ingredients (“API’s”) / drug substance and drug
product development for small molecules and biologics. Its service
offering encompasses drug substance/API development, solid state
research and development, pre-formulation, formulation and
development, analytical development, Non-GMP & GMP
manufacturing and clinical packaging and logistics. Operating with
facilities in Europe, North America and India, Eurofins CDMO is
accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and
Health Canada.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 61,000 staff across a
network of ca. 900 laboratories in 61 countries, Eurofins offers a
portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange
(Eurofins Scientific SE (EURONEXT PARIS: ERF)).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117128127/en/
For further information: Cheryl Young VP Business
Development & Project Management Eurofins CDMO Alphora Inc.
Cheryl.Young@bpt.eurofinsca.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2024 to May 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From May 2023 to May 2024